1 completed, 1 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow Yung NA: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer Dapagliflozin (10mg Tab), standard medical care (ADT + NHA) - Prostate Cancer, Metastatic Prostate Cancer | Phase 2 | Recruiting | Yung NA | 68 | 2026-05-01 | 2026-10-28 |
| Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma gemcitabine, Cisplatin - Muscle Invasive Bladder Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma | Phase 2 | Completed | Yung NA | 15 | 2024-02-02 | 2026-10-28 |
Androgen Antagonists (1) · Cisplatin (1) · Gemcitabine (1) · dapagliflozin (1)
China (1) · Hong Kong (1)